SUPREP Bowel Prep

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
SUPREP Bowel Prep
Generic name
SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE
Manufacturer
Braintree Laboratories, Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
2f5f06de-ee98-44c0-be7e-9a998d1e5c16
SPL ID
5d537ee4-dc8c-32dd-e063-6294a90a4fbe
Version
10
Effective date
2026-10-08
Source export date
2026-11-13
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 17:15:39
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Risk of fluid and electrolyte abnormalities : Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use. ( 5.1 , 7.1 ) Cardiac arrhythmias : Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. ( 5.2 ) Seizures : Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold. ( 5.3 , 7.1 ) Patients with renal impairment or taking concomitant medications that affect renal function : Use caution, ensure adequate hydration and consider laboratory testing. ( 5.4 , 7.1 ) Suspected GI obstruction or perforation : Rule out the diagnosis before administration. ( 4 , 5.6 ) Patients at risk for aspiration : Observe during administration. ( 5.7 ) 5.1 Serious Fluid and Serum Chemistry Abnormalities Advise all patients to hydrate adequately before, during, and after the use of SUPREP Bowel Prep Kit. If a patient develops significant vomiting or signs of dehydration after taking SUPREP Bowel Prep Kit, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN). Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with SUPREP Bowel Prep Kit. Use SUPREP Bowel Prep Kit with caution in patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions ( 7.1 )] . SUPREP Bowel Prep Kit can cause temporary elevations in uric acid [see Adverse Reactions ( 6.1 )] . Uric acid fluctuations in patients with gout may precipitate an acute flare. The potential for uric acid elevation should be considered before administering SUPREP Bowel Prep Kit to patients with gout or other disorders of uric acid metabolism. 5.2 Cardiac Arrhythmias There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing SUPREP Bowel Prep Kit for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. 5.3 Seizures There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities. Use caution when prescribing SUPREP Bowel Prep Kit for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia [see Drug Interactions ( 7.1 )] . 5.4 Use in Patients with Risk of Renal Injury Use SUPREP Bowel Prep Kit with caution in patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs) [see Drug Interactions ( 7.1 )] . These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration with SUPREP Bowl Prep Kit and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Use in Specific Populations ( 8.6 )] . 5.5 Colonic Mucosal Ulcerations and Ischemic Colitis Osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and SUPREP Bowel Prep Kit may increase these risks [see Drug Interactions ( 7.3 )] . Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD). 5.6 Use in Patients with Significant Gastrointestinal Disease If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering SUPREP Bowel Prep Kit [see Contrandications ( 4 )] . Use with caution in patients with severe active ulcerative colitis. 5.7 Aspiration Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of SUPREP Bowel Prep Kit solution. Observe these patients during administration of SUPREP Bowel Prep Kit solution. Use with caution in these patients.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions are: Adults (>2%): overall discomfort, abdominal distention, abdominal pain, nausea, and vomiting. ( 6.1 ) Pediatric Patients (>10%): nausea, abdominal pain, abdominal bloating and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Braintree Laboratories, Inc. at 1-800-874-6756 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . The following important adverse reactions for bowel preparations are described elsewhere in the labeling: Serious Fluid and Serum Chemistry Abnormalities [see Warnings and Precautions ( 5.1 )] Cardiac Arrhythmias [see Warnings and Precautions ( 5.2 )] Seizures [see Warnings and Precautions ( 5.3 )] Use in Patients with Risk of Renal Injury [see Warnings and Precautions ( 5.4 )] Colonic Mucosal Ulceration and Ischemic Colitis [see Warnings and Precautions ( 5.5 )] Patients with Significant Gastrointestinal Disease [see Warnings and Precautions ( 5.6 )] Aspiration [see Warnings and Precautions ( 5.7 )] 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in clinical studies of another drug and may not reflect the rates observed in practice. Adults The safety of SUPREP Bowel Prep Kit was evaluated in a multi-center, randomized, active controlled trial in 379 adult patients undergoing colonoscopy [see Clinical Studies ( 14 )] . Most Common Adverse Reactions Table 1 shows the most common adverse reactions reported in at least 2% of patients receiving SUPREP Bowel Prep Kit or the control (a bowel prep containing polyethylene glycol and electrolytes (PEG + E)) administered in split-dose (2-day) regimens. Table 1: Common Adverse Reactions* in Adult Patients Undergoing Colonoscopy in a Randomized, Active Controlled Trial * reported in at least 2% of patients Symptom Split-Dose (2-Day) Regimen SUPREP % N=190 PEG + E product % N=189 Overall Discomfort 54 67 Abdominal Distension 40 52 Abdominal Pain 36 43 Nausea 36 33 Vomiting 8 4 Laboratory Abnormalities Table 2 shows the most common laboratory abnormalities (at least 10% in either treatment group and more than 2% difference between groups) for patients who developed new abnormalities of important electrolytes and uric acid after completing the bowel preparation with either SUPREP Bowel Prep Kit or PEG+E administered as a split-dose (2-day) regimen. Table 2: Adult Patients with Normal Baseline Serum Chemistry with A Shift to an Abnormal Value While on the Split-Dose (2-Day) Regimen 1 1 The study was not designed to support comparative claims for the laboratory abnormalities reported in this table. 2 Percent (n/N) of patients where N=number of patients with normal baseline who had abnormal values at the timepoint(s) of interest. Day of Colonoscopy N (%) 2 Day 30 N (%) 2 Bicarbonate (low) SUPREP 20 (13) 7 (4) PEG + Electrolytes 24 (15) 4 (3) Bilirubin, total (high) SUPREP 14 (9) 0 (0) PEG + Electrolytes 20 (12) 3 (2) BUN (high) SUPREP 2 (2) 14 (11) PEG + Electrolytes 4 (3) 19 (15) Calcium (high) SUPREP 16 (10) 8 (5) PEG + Electrolytes 6 (4) 6 (4) Chloride (high) SUPREP 4 (2) 6 (4) PEG + Electrolytes 20 (12) 6 (4) Osmolality (high) SUPREP 8 (6) NA PEG + Electrolytes 19 (13) NA Uric acid (high) SUPREP 27 (24) 13 (12) PEG + Electrolytes 12 (10) 20 (17) Less Common Adverse Reactions AV Block (1 case) and CK increase. Adverse Reactions with Unapproved Use In another study of 408 adult patients, higher rates of the following adverse reactions and laboratory abnormalities were reported in patients treated with SUPREP Bowel Prep Kit as an evening-only (1-day) regimen compared to the split-dose (2-day) regimen. overall discomfort, abdominal distention, nausea, and vomiting total bilirubin (high), BUN (high), creatinine (high), osmolality (high), potassium (high) and uric acid (high) Administration of SUPREP Bowel Prep Kit in an evening-only (1-day) dosing regimen is not recommended. Pediatrics 12 Years to 16 Years of Age The safety of SUPREP Bowel Prep Kit was evaluated in a single dose-ranging clinical trial of 89 pediatric patients aged 12 years to 16 years [see Clinical Studies ( 14 )] . In 26 pediatric patients who received SUPREP Bowel Prep Kit (two 4.5-ounce doses), the most common adverse reactions (> 10%) were nausea, abdominal pain, abdominal bloating, and vomiting.

adverse reactions table

<table ID="t1" width="100%"> <caption>Table 1: Common Adverse Reactions* in Adult Patients Undergoing Colonoscopy in a Randomized, Active Controlled Trial </caption> <col width="28.900%" align="left"/> <col width="24.000%" align="left"/> <col width="11.550%" align="left"/> <col width="35.550%" align="left"/> <tfoot> <tr styleCode="First Last"> <td colspan="5" align="left" valign="top"> <paragraph styleCode="First Footnote"> <sup>*</sup> reported in at least 2% of patients </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" align="left" styleCode="Botrule Lrule Rrule Toprule" valign="middle"> <content styleCode="bold">Symptom</content> </td> <td align="left" styleCode="Botrule Toprule" valign="top"/> <td colspan="2" align="left" styleCode="Botrule Rrule Toprule" valign="top"> <content styleCode="bold">Split-Dose (2-Day) Regimen</content> </td> </tr> <tr> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top"> <paragraph>SUPREP</paragraph> <paragraph>% N=190 </paragraph> </td> <td align="center" styleCode="Botrule Rrule" valign="top"> <paragraph>PEG + E product</paragraph> <paragraph>% N=189 </paragraph> </td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Overall Discomfort</td> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">54</td> <td align="center" styleCode="Botrule Rrule" valign="top">67</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Abdominal Distension</td> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">40</td> <td align="center" styleCode="Botrule Rrule" valign="top">52</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Abdominal Pain</td> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">36</td> <td align="center" styleCode="Botrule Rrule" valign="top">43</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Nausea</td> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">36</td> <td align="center" styleCode="Botrule Rrule" valign="top">33</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Vomiting</td> <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">8</td> <td align="center" styleCode="Botrule Rrule" valign="top">4</td> </tr> </tbody> </table>

adverse reactions table

<table ID="t2" width="100%"> <caption>Table 2: Adult Patients with Normal Baseline Serum Chemistry with A Shift to an Abnormal Value While on the Split-Dose (2-Day) Regimen <sup>1</sup> </caption> <col width="25.000%" align="left"/> <col width="25.000%" align="left"/> <col width="25.000%" align="left"/> <col width="25.000%" align="left"/> <tfoot> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="First Footnote"> <sup>1</sup> The study was not designed to support comparative claims for the laboratory abnormalities reported in this table. </paragraph> </td> </tr> <tr> <td colspan="5" align="left" valign="top"> <paragraph styleCode="First Footnote"> <sup>2</sup> Percent (n/N) of patients where N=number of patients with normal baseline who had abnormal values at the timepoint(s) of interest. </paragraph> </td> </tr> </tfoot> <tbody> <tr> <td align="left" styleCode="Botrule Lrule Rrule Toprule" valign="top"/> <td align="left" styleCode="Botrule Rrule Toprule" valign="top"/> <td align="center" styleCode="Botrule Rrule Toprule" valign="top"> <content styleCode="bold">Day of Colonoscopy N (%) <sup>2</sup> </content> </td> <td align="center" styleCode="Botrule Rrule Toprule" valign="top"> <content styleCode="bold">Day 30 N (%) <sup>2</sup> </content> </td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Bicarbonate (low)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">20 (13)</td> <td align="center" styleCode="Botrule Rrule" valign="top">7 (4)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">24 (15)</td> <td align="center" styleCode="Botrule Rrule" valign="top">4 (3)</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Bilirubin, total (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">14 (9)</td> <td align="center" styleCode="Botrule Rrule" valign="top">0 (0)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">20 (12)</td> <td align="center" styleCode="Botrule Rrule" valign="top">3 (2)</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">BUN (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">2 (2)</td> <td align="center" styleCode="Botrule Rrule" valign="top">14 (11)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">4 (3)</td> <td align="center" styleCode="Botrule Rrule" valign="top">19 (15)</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Calcium (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">16 (10)</td> <td align="center" styleCode="Botrule Rrule" valign="top">8 (5)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">6 (4)</td> <td align="center" styleCode="Botrule Rrule" valign="top">6 (4)</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Chloride (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">4 (2)</td> <td align="center" styleCode="Botrule Rrule" valign="top">6 (4)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">20 (12)</td> <td align="center" styleCode="Botrule Rrule" valign="top">6 (4)</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Osmolality (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">8 (6)</td> <td align="center" styleCode="Botrule Rrule" valign="top">NA</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">19 (13)</td> <td align="center" styleCode="Botrule Rrule" valign="top">NA</td> </tr> <tr> <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Uric acid (high)</td> <td align="center" styleCode="Botrule Rrule" valign="top">SUPREP</td> <td align="center" styleCode="Botrule Rrule" valign="top">27 (24)</td> <td align="center" styleCode="Botrule Rrule" valign="top">13 (12)</td> </tr> <tr> <td align="left" styleCode="Botrule Lrule Rrule" valign="top"/> <td align="center" styleCode="Botrule Rrule" valign="top">PEG + Electrolytes</td> <td align="center" styleCode="Botrule Rrule" valign="top">12 (10)</td> <td align="center" styleCode="Botrule Rrule" valign="top">20 (17)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.